Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK - Concepedia

Concepedia

Publication | Closed Access

Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

103

Citations

35

References

2008

Year

Ray Gani, Gavin Giovannoni, David O. Bates, Belinda Kemball, Steve Hughes, John Kerrigan

PharmacoEconomics

Disease ManagementClinical EffectivenessOther Disease-modifying TherapiesClinical EpidemiologyClinical TrialsCost-effectiveness AnalysesCost EffectivenessPublic HealthMedicineEpidemiology

References

	Year	Citations

Page 1